These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34380373)

  • 1. The effects of sacubitril/valsartan on heart failure with preserved ejection fraction: a meta-analysis.
    Yuheng J; Yanyan L; Song Z; Yafang Z; Xiaowei M; Jiayan Z
    Acta Cardiol; 2022 Aug; 77(6):471-479. PubMed ID: 34380373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
    Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
    BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.
    Yu W; Zhang H; Shen W; Luo F; Yang S; Gan L; Zhao Y; Yang P; Wu Q
    Front Cardiovasc Med; 2022; 9():897423. PubMed ID: 36158828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    Mou Y; Qin L; Wang L; Guo Y; Zhang X; Yu J
    Altern Ther Health Med; 2024 Apr; 30(4):190-197. PubMed ID: 37917889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis.
    Basile C; Paolillo S; Gargiulo P; Marzano F; Asile G; Parlati ALM; Chirico A; Nardi E; Buonocore D; Colella A; Perrone-Filardi P
    J Cardiovasc Med (Hagerstown); 2023 Jan; 24(1):44-51. PubMed ID: 36574300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis.
    Nie D; Xiong B; Qian J; Rong S; Yao Y; Huang J
    Heart Lung Circ; 2021 May; 30(5):683-691. PubMed ID: 33199181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kommu S; Berg RL
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541798
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial.
    Jering K; Claggett B; Redfield MM; Shah SJ; Anand IS; Martinez F; Sabarwal SV; Seferović PM; Kerr Saraiva JF; Katova T; Lefkowitz MP; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2021 May; 9(5):386-397. PubMed ID: 33714741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Sacubitril-Valsartan in Patients With Various Types of Heart Failure: A Meta-analysis.
    Zhang H; Huetteman AT; Reyes EA; Appelbaum JS
    J Cardiovasc Pharmacol; 2023 Jun; 81(6):434-444. PubMed ID: 37000983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.
    Mattumpuram J; Maniya MT; Fernandes CAL; Sohail CS; Ahmed A; Khan R; Hamza M; Ali K
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102167. PubMed ID: 37871711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.
    Yang HR; Xu XD; Shaikh AS; Zhou BT
    Ann Pharmacother; 2023 Aug; 57(8):907-917. PubMed ID: 36475871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials.
    Zhang H; Huang T; Shen W; Xu X; Yang P; Zhu D; Fang H; Wan H; Wu T; Wu Y; Wu Q
    ESC Heart Fail; 2020 Dec; 7(6):3841-3850. PubMed ID: 32977362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.
    Vaduganathan M; Claggett BL; Desai AS; Anker SD; Perrone SV; Janssens S; Milicic D; Arango JL; Packer M; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2020 Jan; 75(3):245-254. PubMed ID: 31726194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
    Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
    Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of low-dose sacubitril/valsartan in heart failure patients: A systematic review and meta-analysis.
    Chen WW; Jiang J; Gao J; Zhang XZ; Li YM; Liu YL; Dang HQ
    Clin Cardiol; 2023 Mar; 46(3):296-303. PubMed ID: 36648084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.